Effect of memantine on resting state default mode network activity in Alzheimer's disease

Drugs and Aging

Volumn 28, Issue 3, 2011, Pages 205-217

  Lorenzi, Marco ^a,b   Beltramello, Alberto ^c   Mercuri, Nicola B ^d   Canu, Elisa ^a   Zoccatelli, Giada ^c   Pizzini, Francesca B ^c   Alessandrini, Franco ^c   Cotelli, Maria ^a   Rosini, Sandra ^a   Costardi, Daniela ^a   Caltagirone, Carlo ^d   Frisoni, Giovanni B ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b INRIA   (France)

^c MAGGIORE HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alzheimer's disease, treatment; Memantine, therapeutic use

Indexed keywords

ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; DIURETIC AGENT; HYPNOTIC AGENT; MEMANTINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CUNEUS; DEFAULT MODE NETWORK; DRUG EFFECT; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PRECUNEUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC TEST;

AGED; ALZHEIMER DISEASE; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; REST;

EID: 79951869793     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11586440-000000000-00000     Document Type: Article

References (59)

1. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 2005; (3): CD003154
2. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80 (6): 600-7
3. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14 (8): 704-5
4. Tariot PN, Farlow MR, Grossberg GT. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291 (3): 317-24 (Pubitemid 38101604)
5. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008; 13 (1): 97-107 (Pubitemid 351365621)
6. Schmidt R, Ropele S, Pendl B, et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry 2008; 79 (12): 1312-17
7. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007; 53 (6): 699-723 (Pubitemid 47532143)
8. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse 2008; 62 (2): 149-53
9. Giustizieri M, Cucchiaroni ML, Guatteo E, et al. Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta. J Pharmacol Exp Ther 2007; 322 (2): 721-9 (Pubitemid 47105814)
10. Hesse S, Ballaschke O, Barthel H, et al. Dopamine transporter imaging in adult patients with attention-deficit/ hyperactivity disorder. Psychiatry Res 2009; 171 (2): 120-8
11. Gilden DL, Marusich LR. Contraction of time in attentiondeficit hyperactivity disorder. Neuropsychology 2009; 23 (2): 265-9
12. Monastero R, Camarda C, Pipia C, et al. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007; 78 (5): 546 (Pubitemid 46662914)
13. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 2007; 8 (9): 700-11 (Pubitemid 47283145)
14. Fransson P. How default is the default mode of brain function? Further evidence from intrinsic BOLD signal fluctuations. Neuropsychologia 2006; 44 (14): 2836-45 (Pubitemid 44511969)
15. Gusnard DA, Akbudak E, Shulman GL, et al. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A 2001; 98: 4259-64 (Pubitemid 32249932)
16. Broyd SJ, Demanuele C, Debener S, et al. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev 2009; 33 (3): 279-96
17. Rombouts S, Barkhof F, Goekoop R, et al. Altered resting state networks in mild cognitive impairment and mild Alzheimer's. Hum Brain Mapp 2005; 26: 231-9 (Pubitemid 41759880)
18. Liu Y, Wang K, Yu C, et al. Regional homogeneity, functional connectivity and imaging markers of Alzheimer's disease: a review of resting-state fMRI studies. Neuropsychologia 2008; 46 (6): 1648-56
19. Greicius MD, Srivastava G, Reiss AL, et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004; 101: 4637-42 (Pubitemid 38437463)
20. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-17 (Pubitemid 41208641)
21. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357 (9263): 1191-4 (Pubitemid 32378696)
22. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration.Ann Intern Med 2001; 134 (8): 663-94
23. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (7): 939-44
24. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4 (Pubitemid 23346995)
25. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7 (5): 486-8 (Pubitemid 10073130)
26. Protocollo MEM-T V0 [in Italian]. Brescia: Laboratorio di Epidemiologia e Neuroimaging, IRCCS [online]. Available from URL: http://www.centroalzheimer. it/Public/Protocollo-MEM-T0.doc [Accessed 2010 Nov 26]
27. Lezak MD, Howieson DB, Loring DW, et al. Neuropsychological assessment. 4th ed. New York (NY): Oxford University Press, 2004
28. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (3): 189-98
29. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44 (12): 2308-14
30. Eshed I, Althoff CE, Hamm B, et al. Claustrophobia and premature termination of magnetic resonance imaging examinations. J Magn Reson Imaging 2007; 26 (2): 401-4 (Pubitemid 47257740)
31. Calhoun VD, Adali T, Pearlson GD, et al. A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp 2001; 14 (3): 140-51 (Pubitemid 33032347)
32. Correa N, Adali T, Calhoun VD. Performance of blind source separation algorithms for fMRI analysis using a group ICA method. Magn Reson Imaging 2007; 25 (5): 684-94 (Pubitemid 46817794)
33. Maldjian JA, Laurienti PJ, Kraft RA, et al. An automated method for neuroanatomic and cytoarchitectonic atlasbased interrogation of fMRI data sets. Neuroimage 2003; 19 (3): 1233-9 (Pubitemid 36918259)
34. Hoyer S. Age as risk factor for sporadic dementia of the Alzheimer type? Ann N Y Acad Sci 1994 May 31; 719: 248-56
35. Noda M, Nakanishi H, Akaike N. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 1999; 92 (4): 1465-74 (Pubitemid 29292581)
36. Harris NG, Plant HD, Inglis BA, et al. Neurochemical changes in the cerebral cortex of treated and untreated hydrocephalic rat pups quantified with in vitro 1H-NMR spectroscopy. J Neurochem 1997; 68 (1): 305-12 (Pubitemid 26427321)
37. Magistretti PJ, Pellerin L. Astrocytes couple synaptic activity to glucose utilization in the brain. News Physiol Sci 1999 Oct; 14: 177-82
38. Wu J, Anwyl R, Rowan MJ. beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 1995; 6 (17): 2409-13
39. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006; 6 (1): 61-7 (Pubitemid 43103820)
40. Gruetter R, Seaquist ER, Kim S, et al. Localized in vivo 13C-NMR of glutamate metabolism in the human brain: initial results at 4 tesla. Dev Neurosci 1998; 20 (4-5): 380-8 (Pubitemid 28495533)
41. Shen J, Petersen KF, Behar KL, et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci U S A 1999; 96 (14): 8235-40 (Pubitemid 29328438)
42. Sibson NR, Dhankhar A, Mason GF, et al. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A 1998; 95 (1): 316-21 (Pubitemid 28103951)
43. Aubert A, Pellerin L, Magistretti PJ, et al. A coherent neurobiological framework for functional neuroimaging provided by a model integrating compartmentalized energy metabolism. Proc Natl Acad Sci USA 2007; 104 (10): 4188-93 (Pubitemid 47181600)
44. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 1999; 354 (1387): 1155-63 (Pubitemid 29400898)
45. Lin AP, Shic F, Enriquez C, et al. Reduced glutamate neurotransmission in patients with Alzheimer's disease: an in vivo (13) C magnetic resonance spectroscopy study. MAGMA 2003; 16 (1): 29-42
46. Parpura-Gill A, Beitz D, Uemura E. The inhibitory effects of beta amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res 1997; 754: 65-71 (Pubitemid 27170252)
47. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94 (Pubitemid 27304784)
48. Damoiseaux JS, Keller KE, Menon V, et al. Default mode network connectivity tracks clinical progression in Alzheimer's disease. San Francisco (CA): Organization for the Human Brain Mapping, 2009
49. Peters M, Romieu P, Maurice T, et al. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004; 19 (8): 2212-20 (Pubitemid 38582209)
50. Meisner F, Scheller C, Kneitz S, et al.Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 2008; 33 (9): 2228-36 (Pubitemid 351992085)
51. Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. PLoS Comput Biol 2007; 3 (2): e17
52. Thomas TC, Grandy DK, Gerhardt GA, et al. Decreased dopamine D4 receptor expression increases extracellular glutamate and alters its regulation in mouse striatum. Neuropsychopharmacology 2009; 34 (2): 436-45
53. Konradi C, Leveque JC, Hyman SE. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J Neurosci 1996; 16 (13): 4231-9 (Pubitemid 26192418)
54. Keefe KA, Ganguly A. Effects of NMDA receptor antagonists on D1 dopamine receptor-mediated changes in striatal immediate early gene expression: evidence for involvement of pharmacologically distinct NMDA receptors? Dev Neurosci 1998; 20 (2-3): 216-8
55. Northoff G, Walter M, Schulte RF, et al. GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI. Nat Neurosci 2007; 10 (12): 1515-7 (Pubitemid 350175872)
56. Molinaro G, Battaglia G, Riozzi B, et al. Memantine treatment reduces the expression of the K(+)/CL(-)cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABA(A) receptor activation in mice. Brain Res 2009; 1265: 75-9
57. Song MS, Rauw G, Baker GB, et al. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 2008; 28 (10): 1989-2002
58. Frisoni GB, Fox NC, Jack CR, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010 Feb; 6 (2): 67-77
59. Lin Q, Zheng Y, Yin F, et al. A fast algorithm for one-unit ICA-R. Information Sci 2007; 177: 1265-75 (Pubitemid 44908296)